SWITCH:HM3中阿哌沙班与维生素K的对比
SWITCH试验:一项关于阿哌沙班与维生素K拮抗剂在HeartMate 3左心室辅助装置患者中的随机对照研究
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
研究概览
详细说明
Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.
Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.
Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.
This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Ilan Richter, MD
- 电话号码:3322098345
- 邮箱:ir2498@cumc.columbia.edu
学习地点
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Irving Medical Center
-
接触:
- Ilan Richter, MD
- 电话号码:212-305-7600
- 邮箱:ir2498@cumc.columbia.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
- ≥ 18 years old
- Treated with WARFARIN SODIUM
- Participant must provide written informed consent prior to any clinical investigation related procedure
- In female participants of childbearing capability, not currently pregnant and on appropriate contraception
Exclusion Criteria:
- Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Known allergy to Apixaban
- Bridge to transplant
- Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
- History of major bleeding event with subsequent reduction of INR goal to < 1.8
- Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Aortic root thrombus
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Warfarin
Participants will take warfarin, dose titrated for an INR >= 1.8 |
Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8
其他名称:
|
|
实验性的:Apixaban
Participants wil take apixaban 5 mg bid |
Apixaban 5 mg bid (twice a day)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Survival free of major hemocompatibility related adverse event
大体时间:12 months
|
Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups. |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Non-surgical Major Hemorrhagic Events
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Non-surgical Major Thrombotic Events
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Survival
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Stroke Rates
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Pump Thrombosis Rates
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Bleeding Rates
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
|
Rates of listing for Heart Transplant
大体时间:12 months
|
Rates will be compared between study groups. |
12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
发生不良事件患者的阿哌沙班水平
大体时间:12个月
|
12个月
|
|
|
Patient functional status
大体时间:12 months
|
Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome. |
12 months
|
|
Patient QOL
大体时间:12 months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status. |
12 months
|
|
LVAD device speed
大体时间:12 months
|
LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM. |
12 months
|
|
LVAD device flow
大体时间:12 months
|
LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min. |
12 months
|
|
LVAD device pulsatility index
大体时间:12 months
|
LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units). |
12 months
|
|
LVAD device power
大体时间:12 months
|
LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W. |
12 months
|
|
Right atrial pressure
大体时间:12 months
|
Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg. |
12 months
|
|
Right ventricular systolic pressure
大体时间:12 months
|
Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Right ventricular diastolic pressure
大体时间:12 months
|
Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery systolic pressure
大体时间:12 months
|
Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Pulmonary artery diastolic pressure
大体时间:12 months
|
Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery mean pressure
大体时间:12 months
|
Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary capillary wedge pressure
大体时间:12 months
|
Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg. |
12 months
|
|
Cardiac output
大体时间:12 months
|
Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min. |
12 months
|
|
Invasive hemodynamics
大体时间:12 months
|
Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2. |
12 months
|
|
Drive line infection rates
大体时间:12 months
|
Rate of drive line infections will be compared between study groups. |
12 months
|
|
VAD coordinator time
大体时间:12 months
|
Means will be compared between study groups. |
12 months
|
|
Laboratory monitoring
大体时间:12 months
|
A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts) |
12 months
|
|
Days hospitalized
大体时间:12 months
|
Means will be compared between study groups. |
12 months
|
|
Caregiver burden
大体时间:12 months
|
Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty). |
12 months
|
|
Time in therapeutic range in the warfarin sodium group
大体时间:12 months
|
Means, as well as rates above 70%, will be compared between study groups. |
12 months
|
合作者和调查者
调查人员
- 首席研究员:Nir Uriel, MD、New York Presbyterian / Columbia University Medical Center
出版物和有用的链接
一般刊物
- Netuka I, Tucanova Z, Ivak P, Gregor S, Kolesar DM, Marek T, Melenovsky V, Binova J, Dorazilova Z, Hegarova M, Podolec M, Riha H, Connors JM, Mehra MR. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Circulation. 2024 Aug 6;150(6):509-511. doi: 10.1161/CIRCULATIONAHA.124.069726. Epub 2024 Apr 9. No abstract available.
- Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I, Rollins AT, Abdul-Aziz AA, Kennedy J, Tang DG, Klein KM, Casselman S, Vermeulen C, Sheaffer W, Snipes M, Sinha SS, O'Connor CM. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. 2024 Sep;12(9):1540-1549. doi: 10.1016/j.jchf.2024.04.013. Epub 2024 May 7.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.